Doxorubicin-Induced Mitochondrial Dysfunction Triggers Cardiomyocyte Apoptosis in H9c2 Myoblasts

Strategic Insights -

Doxorubicin (DOX) is a widely prescribed chemotherapeutic agent known to induce cardiomyocyte apoptosis. Researchers from Coimbra, Portugal, led by V.A. Sardo, discovered that DOX-induced mitochondrial dysfunction is a consequence of nuclear p53 activation rather than a direct effect of the drug on mitochondria. The study, published in Cancer Chemotherapy and Pharmacology, found that H9c2 myoblasts treated with DOX showed nuclear accumulation of the drug, followed by an increase in p53 and a decrease in mitochondrial membrane potential.

Key Takeaways:

  • Doxorubicin (DOX) induces cardiomyocyte apoptosis in H9c2 myoblasts.
  • DOX-induced mitochondrial dysfunction is a consequence of nuclear p53 activation.
  • Pifithrin-alpha, a p53 inhibitor, protected against DOX-induced mitochondrial depolarization, caspase activation, and cell death.

Statistics:

  • 0, 0.5, and 1 mcM DOX were tested in H9c2 myoblasts.
  • DOX induction of cardiomyocyte apoptosis was observed after 24 h of treatment.
  • Pifithrin-alpha protected against DOX-induced mitochondrial depolarization in 85% of H9c2 myoblasts.

Sources:

  • Sardo, V.A., et al. (2009). Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemotherapy and Pharmacology, 64(4), 811-827.
  • University of Coimbra. Department of Zoology. Center for Neuroscience & Cellular Biology.
  • Coimbra, Portugal.
  • Cancer Chimotherapy and Pharmacology journal.